Pfizer Stock Rises Wednesday: What's Going On?
Key takeaways
- Pfizer’s stock gains reflect growing confidence in mRNA cancer treatments after Merck and Moderna’s breakthrough melanoma trial.
- Pfizer shares up 3.27% to $28.15
- 52‑week high $28.74
- Merck/Moderna trial: intismeran autogene (V940/mRNA‑4157) + Keytruda
What happened
Pfizer shares rose 3.27% to $28.15 after Merck and Moderna announced positive Phase 3 results for their mRNA‑based melanoma therapy, boosting confidence in mRNA cancer treatments.
Why it matters
The trial showed the combination of intismeran autogene (V940/mRNA‑4157) with Keytruda improved recurrence‑free survival and delayed distant metastasis, the first time an individualized neoantigen therapy cleared a Phase 3 study. This validates mRNA technology beyond vaccines and lifts sentiment for companies with…
Short-term and longer-term
Short-term. Short‑term traders should watch PFE’s price near the $28.74 52‑week high and the volume spike following the Merck/Moderna announcement.
Longer-term. Over the next few months, investors should monitor how Pfizer’s BioNTech partnership translates into pipeline progress.